On August 24, the third session of the Hematological Tumor Clinical Progress Series Lecture and Exchange Meeting of the Sichuan Bioinformatics Society was successfully held in Qingchuan, Guangyuan. The purpose of this meeting was to promote clinical research and academic exchange in the field of hematological tumors, and to foster innovation and development in medical technology. Professor Jia Yongqian, the chairman of the Artificial Intelligence-Hematological Tumor Branch, and Professor Yuan Ying from the Guangyuan Central Hospital co-hosted this grand event, with Deputy Secretary-General Zhou Jueqiao of the Sichuan Bioinformatics Society attending the meeting.

At the opening ceremony, Chairman Jia Yongqian pointed out that with the continuous advancement of technology and in-depth medical research, we have made significant progress in the diagnosis, treatment, and prevention of hematological tumors. This exchange meeting is precisely to share these achievements, discuss future development directions, and bring more hope and effective treatment plans to patients.

Jia Yongqian Chairman's Speech

Professor Yuan Ying, on behalf of all colleagues at the Guangyuan Central Hospital, expressed the warmest welcome and deepest gratitude to the experts who came from afar. Professor Yuan Ying said that she looks forward to learning cutting-edge medical technology and concepts in this exchange, and through this event, to establish a closer cooperative relationship with experts inside and outside the province, and jointly promote the development of the discipline of hematological tumors.

Yuan Ying Professor's Welcome Speech

Deputy Secretary-General Zhou Jueqiao affirmed the vigorous development of the Artificial Intelligence-Hematological Tumor Branch since its establishment, stating that the Clinical Progress Series Lecture and Exchange Meeting has allowed more medical workers to conveniently obtain cutting-edge information, further improving the diagnosis and treatment level of hematological tumor diseases inside and outside the province. The society will continue to hold more high-quality academic activities.

The first half of the academic meeting was presided over by Professor Jia Yongqian from West China Hospital of Sichuan University and Professor Yuan Ying from Guangyuan Central Hospital. Professor Su Yi from the General Hospital of the Western Theater Command and Professor Zhang Li from West China Hospital of Sichuan University respectively gave academic reports titled "Progress in CAR-T Cell Therapy" and "Progress in MM". The reports focused on the latest progress in CAR-T cell therapy, the choice and optimization of treatment timing for RRMM, bringing rich research results and clinical experience to the participants. Professors Li Xiaoming, Huang Shihua, Ma Liangliang, Zheng Li and other representatives asked questions about the content of the report, discussing the specific practices in the diagnosis and treatment of hematological tumors.

The second half of the meeting was presided over by Professor Li Xiaoming from Southwest Medical University and Professor Zheng Li from Guangyuan Central Hospital. Professor Jiang Ming from West China Hospital of Sichuan University gave a report on "New Progress in the Treatment of DLBCL at EHA & ASCO", focusing on the precise diagnosis of hematological tumors, optimization of treatment strategies, and innovative applications of immunotherapy.

Professor Xiang Qian from Guangyuan Central Hospital, combined with her clinical work in the hospital, deeply analyzed specific cases, combined with the latest research results, and discussed new ideas and methods for the treatment of hematological tumors with the participants.

Subsequently, Professor Jia Yongqian gave a report titled "Progress in the Clinical Application of Chimeric Antigen Receptor T Cell Immunotherapy", which was comprehensive and in-depth, elaborating on the application of CAR-T therapy in autoimmune diseases, emphasizing the need to address the side effects of cytokine release syndrome and neurotoxicity while improving efficacy, and that future research will continue to promote the innovation of CAR-T therapy to achieve breakthroughs in a broader range of diseases.

At the end of the meeting, experts including Jia Yongqian, Yuan Ying, Su Yi, Zheng Li, Cao Jiufang, Chen Sha, Wang Xiumei, and Hu Lianjie, combined with their clinical work experience, conducted a discussion on efficacy evaluation and prognosis analysis, emphasizing the importance of formulating treatment plans based on the specific situation of patients and sharing experience in the application of various diagnostic techniques in the diagnosis of hematological tumors.

Through this meeting, participants gained a deeper understanding of the complexity of hematological tumors, learned the latest diagnostic and treatment strategies, and had a clear understanding of future research directions. We look forward to applying this knowledge to clinical practice to provide patients with higher quality medical services.